Skip to main content
. 2022 May 18;19(4):1248–1258. doi: 10.1007/s13311-022-01237-4

Fig. 3.

Fig. 3

Trends across matrices (serum and plasma), analytes (NfL and pNfH), and platforms (Quanterix Simoa, Siemens Healthineers, ProteinSimple Ella, Euroimmun) of NF prior to phenoconversion. Dotted horizon lines indicate the 95th percentile for the combined control and presymptomatic carrier group. Biological samples and clinical data were from the Pre-fALS (Pre-Symptomatic Familial ALS) study